FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321113597> ?p ?o ?g. }

• W4321113597 endingPage "e311" @default.
• W4321113597 startingPage "e303" @default.
• W4321113597 abstract "First-line FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan, and OXaliplatin) and gemcitabine plus nab-paclitaxel (GnP) have been publicly funded for patients with unresectable locally advanced pancreatic cancer (uLAPC) in Ontario, Canada. We examined the overall survival and surgical resection rate after first-line FOLFIRINOX or GnP and determined the association between resection and overall survival in patients with uLAPC.We conducted a retrospective population-based study including patients with uLAPC who received first-line treatment FOLFIRINOX or GnP from April 2015 to March 2019. The cohort was linked to administrative databases to ascertain demographic and clinical characteristics. Propensity score methods were used to balance differences between FOLFIRINOX and GnP. The Kaplan-Meier method was used to calculate overall survival. Cox regression was used to determine the association between receipt of treatment and overall survival, adjusting for time-dependent surgical resections.We identified 723 patients with uLAPC (mean age = 65.8, 43.5% female) who received FOLFIRINOX (55.2%) or GnP (44.8%). The median overall survival and 1-year overall survival probability were higher for FOLFIRINOX (13.7 months, 54.6%) than for GnP (8.7 months, 34.0%). Post-chemotherapy surgical resection occurred in 89 (12.3%) patients (FOLFIRINOX: 74 [18.5%] versus GnP: 15 [4.6%]), with no difference in survival since surgery between FOLFIRINOX and GnP (P = 0.29). After adjusting time-dependent post-treatment surgical resection, FOLFIRINOX (inverse probability treatment weighting hazard ratio 0.72, 95% confidence interval 0.61, 0.84) was independently associated with improved overall survival.In this real-world population-based study of patients with uLAPC, FOLFIRINOX was associated with improved survival and higher resection rates. FOLFIRINOX was associated with improved survival in patients with uLAPC after accounting for the effect of post-chemotherapy surgical resection, suggesting the benefit of FOLFIRINOX was not solely due to improving resectability." @default.
• W4321113597 created "2023-02-18" @default.
• W4321113597 creator A5002447665 @default.
• W4321113597 creator A5009452194 @default.
• W4321113597 creator A5017077147 @default.
• W4321113597 creator A5017953874 @default.
• W4321113597 creator A5025411824 @default.
• W4321113597 creator A5040161846 @default.
• W4321113597 creator A5053112746 @default.
• W4321113597 creator A5058397486 @default.
• W4321113597 creator A5063835785 @default.
• W4321113597 creator A5070447889 @default.
• W4321113597 creator A5085932488 @default.
• W4321113597 date "2023-05-01" @default.
• W4321113597 modified "2023-09-28" @default.
• W4321113597 title "Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival" @default.
• W4321113597 cites W1530374458 @default.
• W4321113597 cites W1675493788 @default.
• W4321113597 cites W1727989948 @default.
• W4321113597 cites W1998194858 @default.
• W4321113597 cites W2012005360 @default.
• W4321113597 cites W2022501291 @default.
• W4321113597 cites W2036193982 @default.
• W4321113597 cites W2061174719 @default.
• W4321113597 cites W2121608920 @default.
• W4321113597 cites W2126049444 @default.
• W4321113597 cites W2135064511 @default.
• W4321113597 cites W2151253787 @default.
• W4321113597 cites W2165480504 @default.
• W4321113597 cites W2171950337 @default.
• W4321113597 cites W2345822778 @default.
• W4321113597 cites W2465801062 @default.
• W4321113597 cites W2559029437 @default.
• W4321113597 cites W2589807181 @default.
• W4321113597 cites W2590612729 @default.
• W4321113597 cites W2789514564 @default.
• W4321113597 cites W2801301689 @default.
• W4321113597 cites W2810100652 @default.
• W4321113597 cites W2884072889 @default.
• W4321113597 cites W2903623792 @default.
• W4321113597 cites W2917091045 @default.
• W4321113597 cites W2917919815 @default.
• W4321113597 cites W2928824372 @default.
• W4321113597 cites W2947666181 @default.
• W4321113597 cites W2982037555 @default.
• W4321113597 cites W2988728533 @default.
• W4321113597 cites W3043777046 @default.
• W4321113597 cites W3121138383 @default.
• W4321113597 cites W3166051227 @default.
• W4321113597 cites W4231737797 @default.
• W4321113597 doi "https://doi.org/10.1016/j.clon.2023.02.008" @default.
• W4321113597 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36863956" @default.
• W4321113597 hasPublicationYear "2023" @default.
• W4321113597 type Work @default.
• W4321113597 citedByCount "0" @default.
• W4321113597 crossrefType "journal-article" @default.
• W4321113597 hasAuthorship W4321113597A5002447665 @default.
• W4321113597 hasAuthorship W4321113597A5009452194 @default.
• W4321113597 hasAuthorship W4321113597A5017077147 @default.
• W4321113597 hasAuthorship W4321113597A5017953874 @default.
• W4321113597 hasAuthorship W4321113597A5025411824 @default.
• W4321113597 hasAuthorship W4321113597A5040161846 @default.
• W4321113597 hasAuthorship W4321113597A5053112746 @default.
• W4321113597 hasAuthorship W4321113597A5058397486 @default.
• W4321113597 hasAuthorship W4321113597A5063835785 @default.
• W4321113597 hasAuthorship W4321113597A5070447889 @default.
• W4321113597 hasAuthorship W4321113597A5085932488 @default.
• W4321113597 hasConcept C10515644 @default.
• W4321113597 hasConcept C121608353 @default.
• W4321113597 hasConcept C126322002 @default.
• W4321113597 hasConcept C141071460 @default.
• W4321113597 hasConcept C143998085 @default.
• W4321113597 hasConcept C167135981 @default.
• W4321113597 hasConcept C207103383 @default.
• W4321113597 hasConcept C2776694085 @default.
• W4321113597 hasConcept C2777148230 @default.
• W4321113597 hasConcept C2779804826 @default.
• W4321113597 hasConcept C2780258809 @default.
• W4321113597 hasConcept C2780259306 @default.
• W4321113597 hasConcept C2780456651 @default.
• W4321113597 hasConcept C2780962732 @default.
• W4321113597 hasConcept C2908647359 @default.
• W4321113597 hasConcept C44249647 @default.
• W4321113597 hasConcept C50382708 @default.
• W4321113597 hasConcept C526805850 @default.
• W4321113597 hasConcept C71924100 @default.
• W4321113597 hasConcept C99454951 @default.
• W4321113597 hasConceptScore W4321113597C10515644 @default.
• W4321113597 hasConceptScore W4321113597C121608353 @default.
• W4321113597 hasConceptScore W4321113597C126322002 @default.
• W4321113597 hasConceptScore W4321113597C141071460 @default.
• W4321113597 hasConceptScore W4321113597C143998085 @default.
• W4321113597 hasConceptScore W4321113597C167135981 @default.
• W4321113597 hasConceptScore W4321113597C207103383 @default.
• W4321113597 hasConceptScore W4321113597C2776694085 @default.
• W4321113597 hasConceptScore W4321113597C2777148230 @default.
• W4321113597 hasConceptScore W4321113597C2779804826 @default.
• W4321113597 hasConceptScore W4321113597C2780258809 @default.

• next